Christian Enzinger
A5024718915- Multiple Sclerosis Research Studies
- Acute Ischemic Stroke Management
- Advanced Neuroimaging Techniques and Applications
- Cerebrovascular and Carotid Artery Diseases
- Advanced MRI Techniques and Applications
- Intracerebral and Subarachnoid Hemorrhage Research
- Functional Brain Connectivity Studies
- Systemic Lupus Erythematosus Research
- Peripheral Neuropathies and Disorders
- RNA regulation and disease
- Stroke Rehabilitation and Recovery
- Neurological Disease Mechanisms and Treatments
- Polyomavirus and related diseases
- Cerebrovascular and genetic disorders
- Ultrasound and Hyperthermia Applications
- Dementia and Cognitive Impairment Research
- Neuroinflammation and Neurodegeneration Mechanisms
- Traumatic Brain Injury and Neurovascular Disturbances
- Rheumatoid Arthritis Research and Therapies
- Cerebral Venous Sinus Thrombosis
- Intracranial Aneurysms: Treatment and Complications
- Neural dynamics and brain function
- Cerebral Palsy and Movement Disorders
- Long-Term Effects of COVID-19
- Neurological Disorders and Treatments
Medical University of Graz
2016-2025
National Hospital for Neurology and Neurosurgery
2024
University College London
2007-2024
Universitat Autònoma de Barcelona
2018-2024
German Center for Neurodegenerative Diseases
2024
Charité - Universitätsmedizin Berlin
2012-2024
German Centre for Cardiovascular Research
2024
Hospices Civils de Lyon
2024
Université Claude Bernard Lyon 1
2024
University Medical Center Hamburg-Eppendorf
2024
Abstract Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured not only in cerebrospinal fluid but also serum, which allows for repeated assessments. There still limited knowledge regarding the association serum NfL (sNfL) with age subclinical morphologic brain changes their dynamics normal population. We sNfL by single molecule array (Simoa) assay 335 individuals participating population-based cohort study after mean follow-up time 5.9 years (n = 103)....
Abstract White matter lesions progress over time, but the clinical consequences are widely unknown. Three‐hundred twenty‐nine elderly community‐dwelling volunteers underwent serial magnetic resonance imaging scanning and cognitive testing at baseline 3‐ 6‐year follow‐up. We measured changes in white lesion brain parenchymal volumes. After 6 years, median increase load was 0.2cm 3 (interquartile range [IQR], 0.0–0.80cm ) with a maximum of 31.4cm . The loss volume 2.3% (IQR, 1.13–3.58%)....
<b>Objectives: </b> To determine the rate of brain atrophy in neurologically asymptomatic elderly and to investigate impact baseline variables including conventional cerebrovascular risk factors, <i>APOE</i> ε4, white matter hyperintensity (WMH) on its progression. <b>Methods: We assessed parenchymal fraction at subsequent annual volume changes over 6 years for 201 participants (F/M = 96/105; 59.8 ± 5.9 years) Austrian Stroke Prevention Study from 1.5-T MRI scans using SIENA (structural...
Objective Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We investigated whether there is a spatiotemporal pattern of GM that associated with faster disability accumulation MS. Methods analyzed 3,604 brain high‐resolution T1‐weighted magnetic resonance imaging scans from 1,417 participants: 1,214 MS patients (253 clinically isolated syndrome [CIS], 708 relapsing‐remitting [RRMS], 128 secondary‐progressive [SPMS], and 125 primary‐progressive [PPMS]), over an...
See Stankoff and Louapre (doi:10.1093/brain/awy114) for a scientific commentary on this article. Grey matter atrophy is present from the earliest stages of multiple sclerosis, but its temporal ordering poorly understood. We aimed to determine sequence in which grey regions become atrophic sclerosis association with disability accumulation. In longitudinal study, we included 1417 subjects: 253 clinically isolated syndrome, 708 relapsing-remitting 128 secondary-progressive 125...
To assess the time course of brain atrophy and difference across clinical subtypes in multiple sclerosis (MS).The percent volume change (PBVC) was computed on existing longitudinal (2 points) T1-weighted MRI from untreated (trial nontrial) patients with MS. Patients (n = 963) were classified as clinically isolated syndromes suggestive MS (CIS, 16%), relapsing-remitting (RR, 60%), secondary progressive (SP, 15%), primary (9%) The median length follow-up 14 months (range 12-68).There marked...
<h3>Objective</h3> To determine whether brain atrophy and lesion volumes predict subsequent 10 year clinical evolution in multiple sclerosis (MS). <h3>Design</h3> From eight MAGNIMS (MAGNetic resonance Imaging MS) centres, we retrospectively included 261 MS patients with MR imaging at baseline after 1–2 years, Expanded Disability Status Scale (EDSS) scoring years. Annualised whole atrophy, central rates T2 were calculated. Patients categorised by diagnosis as primary progressive (n=77),...
Background and objective: We explored which clinical biochemical variables predict conversion from clinically isolated syndrome (CIS) to definite multiple sclerosis (CDMS) in a large international cohort. Methods: Thirty-three centres provided serum samples 1047 CIS cases with at least two years’ follow-up. Age, sex, presentation, T2-hyperintense lesions, cerebrospinal fluid (CSF) oligoclonal bands (OCBs), CSF IgG index, cell count, 25-hydroxyvitamin D3 (25-OH-D), cotinine titres against...
Purpose To apply quantitative susceptibility mapping (QSM) in the basal ganglia of patients with multiple sclerosis (MS) and relate findings to R2* regard sensitivity for clinical morphologic measures disease severity. Materials Methods The local ethics committee approved this study, all subjects gave written informed consent. Sixty-eight (26 clinically isolated syndrome, 42 relapsing-remitting MS) 23 control underwent 3-T magnetic resonance (MR) imaging. Susceptibility maps were...
Background and Purpose— Strokes have especially devastating implications if they occur early in life; however, only limited information exists on the characteristics of acute cerebrovascular disease young adults. Although risk factors manifestation atherosclerosis are commonly associated with stroke elderly, recent data suggests different causes for young. We initiated prospective, multinational European study Stroke Young Fabry Patients (sifap) to characterize a cohort patients. Methods—...
The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance (MRI) studies. diagnostic value of the in multicenter setting with variety clinical 3 tesla (T) MRI protocols, however, remains unknown.To evaluate sensitivity specificity various lesion criteria differentiating MS non-MS conditions using 3T brain commonly used pulse sequences.This large...
Background and purpose Guidelines on monogenic cerebral small‐vessel disease (cSVD) diagnosis management are lacking. Endorsed by the Stroke Neurogenetics Panels of European Academy Neurology, a group experts has provided recommendations selected cSVDs, i.e. autosomal dominant arteriopathy with subcortical infarcts leukoencephalopathy (CADASIL), recessive (CARASIL), High Temperature Requirement A Serine Peptidase 1 (HTRA1), cathepsin‐A‐related strokes (CARASAL), pontine microangiopathy...
‘Covert’ cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological manifestations, and increases the risk of future stroke, cognitive impairment, dependency, death. These European Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist with clinical decisions about management ccSVD, specifically white matter hyperintensities lacunes, prevent adverse outcomes. The were developed according ESO standard operating...
Anticipating the burden of intracerebral haemorrhage is crucial for proactive management and building resilience against future health challenges. Prior forecasts are based on population demography to a lesser extent epidemiological trends. This study aims utilise selected modifiable risk factors socio-demographic indicators forecast incidence mortality in Europe between 2019 2050.
Direct oral anticoagulants (DOACs) reduce the rate of thromboembolism in patients with atrial fibrillation but benefits and risks survivors intracerebral haemorrhage are uncertain. We aimed to determine whether DOACs risk ischaemic stroke without substantially increasing recurrent haemorrhage. PRESTIGE-AF is a multicentre, open-label, randomised, phase 3 trial conducted at 75 hospitals six European countries. Eligible were aged 18 years or older spontaneous haemorrhage, fibrillation, an...